# Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma

> **NCT06924424** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 105 (estimated)

## Conditions studied

- Multiple Myeloma, Neoplasms

## Interventions

- **DRUG:** Aponermin, pomalidomide, dexamethasone

## Key facts

- **NCT ID:** NCT06924424
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2025-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06924424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06924424, "Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06924424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*